{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:20:03Z","timestamp":1764937203063},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s12029-020-00516-7","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T03:47:28Z","timestamp":1599882448000},"page":"947-951","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma"],"prefix":"10.1007","volume":"52","author":[{"given":"Keiji","family":"Sugiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riko","family":"Nishibori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiyoe","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,12]]},"reference":[{"key":"516_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000109976","volume":"87","author":"H Ahlman","year":"2008","unstructured":"Ahlman H, Nilsson O, McNicol AM, Ruszniewski P, Niederle B, Ricke J, et al. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology. 2008;87:40\u20136. https:\/\/doi.org\/10.1159\/000109976.","journal-title":"Neuroendocrinology"},{"key":"516_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ctrv.2012.06.009","volume":"39","author":"N Fazio","year":"2013","unstructured":"Fazio N, Spada F, Giovannini M. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view. Cancer Treat Rev. 2013;39:270\u20134. https:\/\/doi.org\/10.1016\/j.ctrv.2012.06.009.","journal-title":"Cancer Treat Rev"},{"key":"516_CR3","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","volume":"81","author":"E Mitry","year":"1999","unstructured":"Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufi\u00e9 P, Aparicio T, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81:1351\u20135. https:\/\/doi.org\/10.1038\/sj.bjc.6690325.","journal-title":"Br J Cancer"},{"key":"516_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/jjco\/hyp173","volume":"40","author":"S Iwasa","year":"2010","unstructured":"Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. 2010;40:313\u20138. https:\/\/doi.org\/10.1093\/jjco\/hyp173.","journal-title":"Jpn J Clin Oncol"},{"key":"516_CR5","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1200\/jco.2013.54.5392","volume":"32","author":"J von Pawel","year":"2014","unstructured":"von Pawel J, Jotte R, Spigel DR, O'Brien MER, Socinski MA, Mezger J, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32:4012\u20139. https:\/\/doi.org\/10.1200\/jco.2013.54.5392.","journal-title":"J Clin Oncol"},{"key":"516_CR6","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1200\/jco.2008.18.1974","volume":"26","author":"A Inoue","year":"2008","unstructured":"Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 2008;26:5401\u20136. https:\/\/doi.org\/10.1200\/jco.2008.18.1974.","journal-title":"J Clin Oncol"},{"key":"516_CR7","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/0277-5379(87)90128-3","volume":"23","author":"PE Postmus","year":"1987","unstructured":"Postmus PE, Berendsen HH, van Zandwijk N, Splinter TAW, Burghouts JTM, Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987;23:1409\u201311. https:\/\/doi.org\/10.1016\/0277-5379(87)90128-3.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"516_CR8","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.2147\/cmar.s201048","volume":"11","author":"Y Kitagawa","year":"2019","unstructured":"Kitagawa Y, Osumi H, Shinozaki E, Ota Y, Nakayama I, Suzuki T, et al. Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study. Cancer Manag Res. 2019;11:5757\u201364. https:\/\/doi.org\/10.2147\/cmar.s201048.","journal-title":"Cancer Manag Res"},{"key":"516_CR9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/cad.0000000000000393","volume":"27","author":"T Araki","year":"2016","unstructured":"Araki T, Takashima A, Hamaguchi T, Honma Y, Iwasa S, Okita N, et al. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract. Anti-Cancer Drugs. 2016;27:794\u20139. https:\/\/doi.org\/10.1097\/cad.0000000000000393.","journal-title":"Anti-Cancer Drugs"},{"key":"516_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00280-015-2706-y","volume":"75","author":"K Nio","year":"2015","unstructured":"Nio K, Arita S, Isobe T, Kusaba H, Kohashi K, Kajitani T, et al. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy. Cancer Chemother Pharmacol. 2015;75:829\u201335. https:\/\/doi.org\/10.1007\/s00280-015-2706-y.","journal-title":"Cancer Chemother Pharmacol"},{"key":"516_CR11","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00280-011-1619-7","volume":"68","author":"M Asayama","year":"2011","unstructured":"Asayama M, Fuse N, Yoshino T, Yano T, Tahara M, Doi T, et al. Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases. Cancer Chemother Pharmacol. 2011;68:1325\u201330. https:\/\/doi.org\/10.1007\/s00280-011-1619-7.","journal-title":"Cancer Chemother Pharmacol"},{"key":"516_CR12","doi-asserted-by":"publisher","first-page":"425876","DOI":"10.1155\/2015\/425876","volume":"2015","author":"T Ando","year":"2015","unstructured":"Ando T, Hosokawa A, Yoshita H, Ueda A, Kajiura S, Mihara H, et al. Amrubicin monotherapy for patients with platinum-refractory gastroenteropancreatic neuroendocrine carcinoma. Gastroenterol Res Pract. 2015;2015:425876\u20135. https:\/\/doi.org\/10.1155\/2015\/425876.","journal-title":"Gastroenterol Res Pract"},{"key":"516_CR13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1530\/erc-12-0002","volume":"19","author":"O Hentic","year":"2012","unstructured":"Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo M, et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 2012;19:751\u20137. https:\/\/doi.org\/10.1530\/erc-12-0002.","journal-title":"Endocr Relat Cancer"},{"key":"516_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182\u20138. https:\/\/doi.org\/10.1111\/his.13975.","journal-title":"Histopathology"},{"key":"516_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/s1470-2045(10)70181-9","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol. 2010;11:853\u201360. https:\/\/doi.org\/10.1016\/s1470-2045(10)70181-9.","journal-title":"Lancet Oncol"},{"key":"516_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10147-007-0737-z","volume":"13","author":"N Fuse","year":"2008","unstructured":"Fuse N, Doi T, Ohtsu A, Yano T, Hamamoto Y, Minashi K, et al. Safety of irinotecan and infusional fluorouracil\/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. Int J Clin Oncol. 2008;13:144\u20139. https:\/\/doi.org\/10.1007\/s10147-007-0737-z.","journal-title":"Int J Clin Oncol"},{"key":"516_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"516_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"key":"516_CR19","doi-asserted-by":"publisher","first-page":"18999","DOI":"10.1038\/srep18999","volume":"6","author":"N Horita","year":"2016","unstructured":"Horita N, Yamamoto M, Sato T, Tsukahara T, Nagakura H, Tashiro K, et al. Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients. Sci Rep. 2016;6:18999. https:\/\/doi.org\/10.1038\/srep18999.","journal-title":"Sci Rep"},{"key":"516_CR20","first-page":"1341","volume":"37","author":"I Sato","year":"2010","unstructured":"Sato I, Ueda N, Kinoshita E, et al. Curatively resected case of non-functioning pancreatic neuroendocrine carcinoma with multiple liver metastases after downstaging with S-1 monotherapy. Gan To Kagaku Ryoho. 2010;37:1341\u20134.","journal-title":"Gan To Kagaku Ryoho"},{"key":"516_CR21","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3892\/mco.2015.607","volume":"3","author":"L Wang","year":"2015","unstructured":"Wang L, Song Q, Li J, Chen X. S-1 treatment leading to complete remission of advanced duodenal adenocarcinoma: a case report. Mol Clin Oncol. 2015;3:1184\u20136. https:\/\/doi.org\/10.3892\/mco.2015.607.","journal-title":"Mol Clin Oncol"},{"key":"516_CR22","first-page":"5743","volume":"34","author":"F Hirai","year":"2014","unstructured":"Hirai F, Seto T, Inamasu E, Toyokawa G, Yoshida T, Nosaki K, et al. Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma. Anticancer Res. 2014;34:5743\u20137.","journal-title":"Anticancer Res"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-020-00516-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-020-00516-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-020-00516-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:02:54Z","timestamp":1631404974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-020-00516-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,12]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1007\/s12029-020-00516-7","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,12]]},"assertion":[{"value":"7 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Institutional Review Board (No. 2020-002).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The need for informed consent was waived owing to the retrospective nature of the study. An opt-out option was provided instead.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}